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Abstract
Abdominal aortic aneurysms (AAAs), which commonly occur among elderly individuals, are
accompanied by a risk of rupture with a high mortality rate. Although eicosapentaenoic acid
(EPA) has been reported to prevent AAA formation, the mechanism by which EPA works
on vascular smooth muscle cells is unknown. This study aimed to investigate the mecha-
nism by which orally-administered EPA prevents the formation of severe AAAs that develop
in Osteoprotegerin (Opg) knockout (KO) mice. In the CaCl2-induced AAA model, EPA
attenuated the enhanced progression of AAAs in Opg-KO mice, including the increase in
aortic diameter with destruction of elastic fibers in the media. Immunohistochemical analy-
ses showed that EPA reduced the phosphorylation of transforming growth factor beta-
activated kinase-1/Map3k7 (Tak-1) and c-Jun NH2-terminal kinase (JNK), as well as the
expression of Matrix metalloproteinase-9 (Mmp-9) in the media of the aorta. In smooth
muscle cell cultures, rh-TRAIL-induced activation of the Tak-1-JNK pathway and increase
in Mmp-9 expression were inhibited by EPA. Moreover, GW9508, a specific ligand for G-
protein coupled receptor (Gpr)-120/Free fatty acid receptor (Ffar)-4, mimicked the effects
of EPA. The effects of EPA were abrogated by knockdown of the Gpr-120/Ffar-4 receptor
gene. Our data demonstrate that the Trail-Tak-1-JNK-Mmp-9 pathway is responsible for
the enhancement of AAAs in Opg-KO mice, and that EPA inhibits the Tak-1-JNK pathway
by activating Gpr-120/Ffar-4, which results in the attenuation of AAA development.
Introduction
An abdominal aortic aneurysm (AAA) is a condition in which the abdominal aorta is
expanded, leading to rupture with a high mortality rate. Destructionof medial elastic fibers
and infiltration of macrophages into AAA lesions are considered as the main causes of AAA
formation[1]. Degradation of aortic medial elastic fibersmay be induced by imbalances
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between the proteolytic activities of matrix metalloproteinases, such as MMP-2 and MMP-9,
and their inhibitors, the tissue inhibitors of metalloproteinases (Timp-1). The expression of
both is reported to be elevated during aneurysm development[2–6]. It has been reported that
MMPs are induced by activation of the JNK pathway[5,7,8] in macrophages and vascular
smoothmuscle cells (SMCs), and that inhibition of the JNK pathway results in AAA regression
[7]. Pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-
1, are known to activate the JNK pathway[9].
OPG, which is secreted from osteoblasts, promotes bone formation by acting as a decoy
receptor for the receptor activator of nuclear factor kappa-B ligand (Rankl), a factor that pro-
motes the differentiation and activation of osteoclasts during osteogenesis[10,11].OPG is
expressed in vascular SMCs, and plays roles in preventing arterial calcification and stabilizing
plaque formation in animal models[12–14].We recently reported that Opg prevents the devel-
opment of AAAs, given the reduced formation of AAAs with complete disruption of medial
elastic fibers inOpg-KO mice[15]. TNF-related apoptosis inducing ligand (Trail), which was
increased inOpg-KO mice, induced the expression of Mmp-9 through JNK, and of Timp-1
through nuclear factor (NF)-κB pathways, in aortic SMCs. Since OPG functions as a decoy
receptor for Trail, we concluded that Opg prevents AAA formation through its antagonistic
effect on Trail.
Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid (ω-3 PUFA), showed
great promise in the prevention of cardiovascular diseases through its anti-inflammatory
effects[16–18]. In particular, EPA attenuated the development of AAAs through suppression
of tissue remodeling and inhibition of macrophage-mediated inflammation [19] [20]. The
molecularmechanism underlying EPA’s anti-inflammatory effects in the vascular system is not
yet fully understood. Recently, EPA has been reported to function as a ligand for Gpr-120/
Ffar-4. Activation of Gpr-120/Ffar-4 was shown to induce the release of glucagon-like peptide
(GLP)-1 into the intestine[21], and also exhibited a possible anti-inflammatory effect by inhib-
iting JNK and NF-κB pathways in macrophages and adipocytes[22]. It is unknownwhether
Gpr-120/Ffar-4 is expressed in vascular SMCs, and whether it plays a role in AAA formation.
Here, we report that orally-administered EPA prevents the enlargement of AAAs inOpg-
KO mice in a CaCl2-induced AAAmodel.We found the size of the abdominal aorta to be sig-
nificantly reduced inOpg-KOmice fed an EPA (+) diet. In vascular SMCs, EPA and GW9508,
agonists of Gpr-120/Ffar-4, significantly reduced the TRAIL-induced expression ofMmp-9 by
inhibiting the JNK pathway. This suppression was reversed by knock-down of Gpr-120/Ffar-4
expression. Our findings suggest that EPA can prevent the enlargement of AAAs by activating
Gpr-120/Ffar-4-mediated signaling in aortic SMCs.
Materials and Methods
Generation of a Mouse Model for AAAs
The experiment protocol was approved by the Committee of Animal Experimentation at Hiro-
shima University (A08-32) and carried out in accordance with this protocol. All surgeries were
performed under sodium phenobarbital anesthesia, and efforts were made to minimize suffer-
ing during and after surgery. Animals were sacrificedby anesthetic overdose with sodiumphe-
nobarbital. Wild-type and Opg-KO male mice of the C57BL/6J strain (CLEA Japan, Inc.) were
used. AAA was induced by the CaCl2 method as described in our previous report[15]. Briefly,
we added 50 μL of 0.5 M CaCl2 to a small piece of cotton and placed it on the aortic wall for 15
min. The CaCl2-treated area was limited to 1/2 to 1/3 of the circumference surface. Character-
istic of our peri-aorticCaCl2 application is minimized invasion of the aorta. The F1-diet,
which does not contain fish meat (Funabashi Farm Co., Ltd.), was mixed 5% (wt/wt) with EPA
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(provided by Mochida Pharmaceutical Co., Ltd.) and fed to mice starting two weeks before
AAA induction up to the point of aorta examination.
Morphological Examination
Paraffin-embeddedaortic tissues were used to generate 6 μm-thick sections that were subse-
quently subjected to hematoxylin & eosin (H&E), Elastica van Gieson (EVG), Aniline Blue-
Azan, or von Kossa staining using standard protocols. The maximum aortic diameter, including
thickened adventitia with inflammation, was measured as the external aortic diameter. For
widths of the medial layers of the aorta, the maximum values were measured on the sides to
which CaCl2 was applied. The means of maximum and minimummeasurements of the internal
cross-sections of the aorta reflect the internal diameter of the aorta. All measurements were per-
formed using Photoshop (Adobe Systems) and Image-J (National Institutes of Health; NIH).
Immunohistochemistry
Prior to staining, sections were pre-incubated in antigen retrieval solution (pH 5.2) at 90°C for
45 minutes, based on the manufacturer’s instructions (Dako). For double-immunohistochem-
istry, antigen-retrieved sections were blocked with 1% bovine serum albumin in 0.1% Tween-
phosphate buffered solution (PBS), incubated with a combination of primary antibodies, and
subsequently incubated with appropriate secondary antibodies, including Alexa Fluor 488 or
555 dyes and conjugated anti-mouse, -rat, -rabbit, or -goat antibodies (donkey, 1:500; Life
Technologies). Sections were then counterstained with 4'-6-diamidino-2-phenylindole (DAPI).
Antibodies for Mmp-9 (goat polyclonal, 1:40; R&D Systems), Trail (rabbit polyclonal, 1:100;
Abcam), phosphorylated-SAPK/JNK (rabbit, 1:100; Cell Signaling),α-smoothmuscle actin
(SMA; mouse, monoclonal, 1:100; Sigma Aldrich), and a polyclonal antibody to GPR-120/
FFAR-4 (rabbit, 1:1000; Cell Signaling), were used as primary antibodies. Signals were detected
using a DMI4000 fluorescencemicroscope (LeicaMicrosystems). Photoshop (Adobe Systems)
or Image-J (NIH) software was used to calculate the signal area, which was automatically
detected based on color, as well as the entire intima-medial area, selected based on morphol-
ogy. The percent positive area for pJNK and Mmp-9 was calculated by dividing the area by the
entire intima-medial region.
Real-Time PCR
Total RNA was isolated using TRIzol (Invitrogen). Reverse transcription was performedwith
the ReverTra Ace1 qPCR RT Kit (TOYOBO). Real-time PCR was conducted using SYBR Pre-
mix Ex Taq II (Takara Bio Inc. and Kapa Biosystems Inc.). Intensities of PCR products were
measured and analyzed using Opticon (MJ Research). The following primers were used for
Mmp-9: forward 5’-GCCCTGGAACTCACACGACA-3’ and reverse 5’-TTGGAAACTCA
CACGCCAGAAG-3’.Amplification conditions were 5 s at 95°C, 20 s at 60°C, and 15 s at 72°C,
for 49 cycles. Internal controls includedG3pdh or β-actin. To detect messenger ribonucleic
acid (mRNA) of Gpr-120/Ffar-4, RNA extracts were amplified by PCR using the following
primers: forward 5’-TGTCCCAACAAGACTACCGAC-3’ and reverse 5’-ACAGTATGGGG
TTTAGGGCAG-3’,with the following conditions: 30 s at 94°C, 30 s at 55°C, and 30 s at 72°C,
for 35 cycles.
Cell Culture
Mouse aortic SMCs were isolated from the abdominal aorta (from the diaphragm to the bifur-
cation) in five-week-oldwild-typemale mice, as previously described[15,23], and maintained
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in Dulbecco'sModified EagleMedium (DMEM) with 10–20% fetal bovine serum (FBS). Cells
were growth arrested at 70–80% confluence via incubation in serum-freemedium for 48 hours
before stimulating cells with rh-TRAIL (CD253; AbD Serotec). Different concentrations of
EPA sodium salt (Sigma Aldrich) in 1% fatty acid-free bovine serum albumin (BSA; Calbio-
chem) in serum-freemediumwere applied to cells two hours before rh-TRAIL induction. Dif-
ferent concentrations of GW9508 (Cayman chemical) for activation of Gpr-120/Ffar-4, and
either AS-601245 (Enzo Life Sciences) or SP600125 (Calbiochem), for inhibition of JNK
activity, were added two hours before rh-TRAIL induction.Gpr-120/Ffar-4 siRNA (Ambion
silencer select) for knock-downwas applied 24 hours before rh-TRAIL induction.
Western Blotting
Cell lysates were prepared from growth-arrested vascular SMCs (VSMCs), which were stimu-
lated with rh-TRAIL and then collected in radioimmunoprecipitation assay (RIPA) lysis buffer
by scraping. Samples containing equal amounts of proteins were separated by sodiumdodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose
membrane. The blot was incubated with a primary antibody (Phospho-SAPK/JNK, rabbit
monoclonal, 1:1000, Cell Signaling; SAPK/JNK, rabbit monoclonal, 1:1000, Cell Signaling;
Phospho-TAK-1, rabbit monoclonal, 1:1000, Cell Signaling; TAK-1, rabbit monoclonal,
1:1000, Cell Signaling) and subsequently with an appropriate secondary antibody. Signals were
visualizedwith the enhanced chemiluminescence (ECL) system (Amersham-Pharmacia Co, U.
K.). Images were captured using Photoshop (Adobe) and densitometry was performed using
Image J software (NIH).
Statistical Analysis
All data were statistically evaluated using Ekuseru-Toukei 2012 software (Social Survey
Research Information Co., Ltd.) and quantitative values are expressed as mean ± standard devi-
ation (SD). For mouse studies, a non-parametric analysis, Kruskal-Wallis test with Scheffe’s
post-hoc analysis or Steel-Dwass post-hoc analysis, was performed. For cell culture experi-
ments, which were performed independently three times, the Mann-Whitney U test was used
for comparisons. For all statistical tests, P<0.05 was considered significant.
Results
EPA Attenuates the Development of AAAs in Opg-KO Mice
In order to examine whether EPA attenuates the development of AAA inOpg-KOmice, we
first measured the size of the aorta in wild-type and Opg-KO mice, which were fed a diet with
(+) or without (-) EPA starting two weeks before AAA induction[7], [15]. In wild-typemice,
regardless of feeding with EPA or not, a significant increase in external aortic diameters was
observed at six weeks after AAA induction (Fig 1A and 1B). No significant difference was
found in external aortic diameters with or without EPA. In Opg-KO mice, the external aortic
diameter was increased at one week. At six weeks, however, obvious enlargement of the exter-
nal aortic diameter was observed in mice fed the EPA (-) diet, while this enlargement was sig-
nificantly reduced in mice fed the EPA (+) diet (Fig 1A and 1B). No significant change in
mouse body weight by EPA was observed (S1A Fig). Sham operations did not result in signifi-
cant changes at any time point (S1B and S1C Fig).
Hematoxylin and eosin staining of aortic sections showed an increase of the internal diame-
ter of the abdominal aorta and thinning of the medial layer at one week in wild-type and Opg-
KO mice fed EPA (-) and (+) diets (Fig 1C–1E). Six weeks later, an increase of the internal
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Fig 1. EPA attenuates progressive dilatation of the abdominal aorta in Opg-KO mice. (A)
Representative aortas are shown at zero, one, and six weeks (w) after application of CaCl2 (AAA) in wild-
type and Opg-KO mice, which were fed diets with (+) or without (-) EPA. Scale bars indicate 1 mm. (B)
Measurements of the external aortic diameter at zero, one, and six weeks after AAA induction with the
indicated diet conditions. (C) Representative H&E stained sections of aortas are shown. Scale bars indicate
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diameter was maintained in both wild-type and Opg-KO mice. The width of the medial layer
was markedly enlarged inOpg-KO mice fed the EPA (-) diet. This enlargement was signifi-
cantly reduced with the EPA (+) diet (Fig 1C and 1E). Elastica van Gieson staining showed
typical wavy lamellae of elastic fibers in the medial layers of wild-type and Opg-KOmice at
day 0 (Fig 1F). In Opg-KOmice fed the EPA (-) diet, disruption of the medial elastic lamellae
was observed at one week after AAA induction; at six weeks, medial elastic lamellae were
completely disrupted. However, inOpg-KO mice fed the EPA (+) diet, elastic fibers were
retained with flattened structures (Fig 1F). This suggests that EPA attenuates the adverse effects
of the loss-of-function of Opg on the extracellularmatrix of the aortic media.
EPA Reduces JNK PhosphorylationandMmp-9 Expression in theMedia of AAAs. We
next assessed JNK phosphorylation and Mmp-9 expression in the AAAmodel. Consistent with
a previous report [15], focal expression of pJNK co-localizedwith Mmp-9 was observed in
Opg-KO mice fed the EPA (-) diet at six weeks (Fig 2A). However, these findings were attenu-
ated in the medial layer of Opg-KO mice fed the EPA (+) diet. Mmp-9 and pJNK double-posi-
tive areas were significantly increased inOpg-KO mice fed the EPA (-) diet compared to mice
fed the EPA (+) diet (Fig 2B and 2C).
EPA Down-regulatesTrail in theMedia of AAAs. Trail is up-regulated in the media of
AAAs inOpg-KOmice [15], and thus we tested whether Trail expression could be reduced with
the EPA (+) diet. In Opg-KOmice fed the EPA (-) diet, Trail was markedly up-regulated in the
outer zone of the medial layer, whereMmp-9 was mostly co-localized (Fig 3A). EPA suppressed
the up-regulation of Trail and Mmp-9 in the media of Opg-KOmice (Fig 3A and S2 Fig).
We previously reported that Trail could induce its own expression, similar to TNF-α [24],
and that its activation could be blocked by the decoy receptor Opg. Given that Trail and p-JNK
are expressed in the medial layer, we hypothesized that Trail could induce its own expression
through the JNK signaling pathway, and examined whether rh-TRAIL-inducedTrail expres-
sion is inhibited by JNK inhibitors (AS-601245, SP-600125) in our SMC culture system. Trail
expression was reduced in a dose-dependentmanner (Fig 3B and 3C), suggesting that Trail
induces its own expression via JNK activation in SMCs.
EPA Down-regulatesMmp-9 Expression by Inhibiting the JNK Pathway in SMCs. Up-
regulation ofMmp-9 expression by rh-TRAIL and TNF-α can occur through the JNK pathway
[8], [15]. Here, we tested whether EPA could inhibit the increase inMmp-9 expression induced
by Trail through JNK phosphorylation in SMCs. EPA reduced Trail-induced JNK phosphory-
lation (Fig 4A) andMmp-9 expression (Fig 4B).
EPA may Prevent AAAs throughGpr-120/Ffar-4 Receptors. To investigate the mecha-
nism by which EPA reduces Trail-induced JNK phosphorylation andMmp-9 expression, we
hypothesized that EPA might function as a ligand for Gpr-120/Ffar-4 and repress JNK signal-
ing.We first examined whether Gpr-120/Ffar-4 is expressed in SMCs. Immunohistochemical
analysis revealed that Gpr-120/Ffar-4 co-localizeswith α-SMA in aortic tissue (Fig 5A). More-
over, Gpr-120/Ffar-4mRNA was detected in SMCs, as determined by RT-PCR analysis (Fig
5B). These findings confirm the expression of Gpr-120/Ffar-4 in SMCs.
EPA has been reported to exert its anti-inflammatory effects by inhibiting the activation of
Tak-1, a kinase for JNK and NF-κB, through Gpr-120/Ffar-4[21]. We first confirmed that
200 μm. (D, E) Measurements of the internal aortic diameter (D) and the width of the medial layer (E) at zero,
one, and six weeks after AAA induction. (F) Representative EVG-stained sections are shown. Collapse of
elastic fibers (arrow) at one week and disruption of elastic lamella (arrowheads) at six weeks are observed in
the medial layers of Opg-KO mice. Scale bars indicate 100 μm. Data are presented as mean ± SD. The
sample number (n) is shown in parentheses. *p<0.05 or **p<0.01, compared at zero, one, and six weeks,
with EPA (-) and (+) diets.
doi:10.1371/journal.pone.0165132.g001
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Trail activates Tak-1 (Fig 5C). We then tested whether EPA or GW9508, an agonist for Gpr-
120/Ffar-4, could reduce the Trail-induced phosphorylation of Tak-1. Tak-1 phosphorylation
was completely inhibited with EPA or GW9508 treatment (Fig 5D and 5E). In addition to Tak-
1 inactivation, JNK phosphorylation andMmp-9 expression were inhibited by GW9508 in a
Fig 2. EPA attenuates the upregulation of Mmp-9 co-localized with pJNK in Opg-KO mice. (A)
Representative double immunofluorescent staining images are shown for pJNK (green) and Mmp-9 (red) at
six weeks (w) after AAA induction in the aortas of wild-type and OPG-KO mice fed EPA (+) and (-) diets.
Rectangles with dotted lines in panels i-l and q-t are magnified in panels m-p and u-x, respectively. The
border of the medial layer (m) with the intima or adventitia (a) is indicated by a white dotted line in panels m-p
and u-x. Nuclei are stained with DAPI (blue). Scale bars represent 100 μm. (B, C) Percentages of stained
areas for pJNK (B) and Mmp-9 (C) in the medial layers were calculated at one and six weeks for each diet
condition. Data are presented as mean ± SD. The number of samples for analysis (n) is shown in
parentheses. *p<0.05, as compared with EPA (-) diet conditions.
doi:10.1371/journal.pone.0165132.g002
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dose-dependentmanner (Fig 5F and 5G). Thus, stimulation of Gpr-120/Ffar-4 by EPA or
GW9508 could inhibit the JNK pathway through inactivation of Tak-1.
To confirmwhether Gpr-120/Ffar-4 is required for the effects of EPA, we knocked down
Gpr-120/Ffar-4 using siRNA (S3 Fig). Knockdown of Gpr-120/Ffar-4 abrogated the inhibitory
effects of EPA on Trail-induced phosphorylation of Tak-1 and JNK (Fig 5H and 5I) and Mmp-
Fig 3. EPA prevents the up-regulation of Trail in Opg-KO mice via inhibition of JNK. (A)
Representative double immunofluorescent staining images for Trail (green) and Mmp-9 (red) are shown at
six weeks after AAA induction in the aortas of wild-type and Opg-KO mice fed an EPA (+) diet. Rectangles
with dotted lines in panels i-l and q-t are magnified in panels m-p and u-x, respectively. The border of the
medial layer (m) with the intima or adventitia (a) is indicated by a white dotted line in panels m-p and u-x.
Nuclei are stained with DAPI (blue). Scale bars represent 100 μm. (B-C) In the SMC culture system, Trail
mRNA expression induced by rh-TRAIL (10 ng/mL) was inhibited by JNK inhibitors AS-601245 (0.2–20 μM)
(B) and SP-600125 (3–30 μM) (C). Data are presented as mean ± SD; *p<0.05, as compared with controls
or Trail alone. Experiments were independently repeated three times.
doi:10.1371/journal.pone.0165132.g003
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9 expression (Fig 5J). These data suggest that the activation of Gpr-120/Ffar-4, induced by
EPA, may be crucial for inhibiting JNK phosphorylation and reducingMmp-9 expression.
Discussion
In this study, we found that EPA prevents disruption of the media in the abdominal aorta of
Opg-KOmice.We previously reported that CaCl2-induced inflammation was prolonged in
Opg-KO mice, and that this resulted in complete destruction of the media[15].We speculated
that, in the absence of Opg, Trail-induced Trail expression forms a vicious cycle that strongly
induces Mmp-9 expression. Here, we demonstrated that this vicious cycle is blocked by EPA.
Upon investigation of the mechanism underlying this effect, we found that EPA reduces the
phosphorylation of Tak-1 and JNK, and down-regulatesMmp-9 expression via Gpr-120/Ffar-4
in cultured SMCs. Epidemiological studies have shown EPA to have inhibitory effects on car-
diovascular events, especially in more severe cases[18].We speculate that, in such cases, the
function of OPGmight be down-regulated or blocked, and that this insufficiency in OPG activ-
ity might worsen the vicious cycle of Trail-induced Trail expression. Our findings suggest that
Fig 4. EPA reduces Trail-induced Mmp-9 expression via JNK. (A) Western blotting analysis for pJNK/JNK from
SMCs, which were cultured with rh-TRAIL (10 ng/mL) for 30 minutes with or without pre-incubation with EPA (0.1–
10 μM). (B) Relative expression levels of Mmp-9 mRNA by qPCR from SMCs cultured with rh-TRAIL induction (10
ng/mL) for six hours with or without pre-incubation with EPA (0.1–10 μM). Data are presented as mean ± SD;
*p<0.05, as compared with controls or Trail alone.
doi:10.1371/journal.pone.0165132.g004
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Fig 5. EPA reduces Mmp-9 expression by inactivating the Tak1-JNK pathway via activation of Gpr-120/
Ffar-4. (A) Representative double immunofluorescent staining image shows Gpr-120/Ffar-4 (green) and α-SMA
(red) in the aortas of wild-type mice. Lower panels are magnified from upper panels. (B) Amplified Gpr-120/Ffar-4
mRNA samples derived from SMCs are shown. (C-F) Western blotting analysis for pTak-1/Tak-1 (C-E) and pJNK/
JNK (F) from SMCs cultured for the indicated periods (C), 15 minutes (D and E), and 30 minutes (F) with rh-TRAIL
EPA Prevents AAA through Gpr-120/Ffar4
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OPG, a protector of bonemetabolism, also plays a protective role in vascular walls, and that
EPA can rescue cells from the negative effects of OPG insufficiency.
Recent reports from two groups suggest that EPA plays a preventive role against AAA for-
mation in different animal models.Wang et al. reported that EPA reduced TNF-α-induced
MMP-9 expression in macrophages [19], and Yoshihara et al. found that EPA reduced the lev-
els of inflammatory cytokines, such as IL-6 and MCP-1, in macrophages[20]. However, neither
group focused on Trail, an inflammatory cytokine, nor did they address the role of SMCs in
AAA formation. Our present study, for the first time, demonstrates a potential role for EPA in
preventing AAAs and down-regulating Trail in SMCs.
Although EPA blocked severe AAA lesions inOpg-KOmice, it did not affect the formation
of AAAs in wild-typemice (Fig 1B). Contrary to our results, Wang et al. showed a significant
reduction of CaCl2-induced AAAs with EPA treatment. Because CaCl2-induced AAA forma-
tion is quite drastic, we decided to weaken the effects of CaCl2 by reducing the amount applied.
Specifically, we restricted the contact area by using a small piece of cotton, and limited the
treatment duration to 15 minutes. As a result, AAA lesions were weak in wild-typemice, to the
extent that no differences were observedbetween EPA (-) and EPA (+) groups. Wang et al. also
used two times higher dose of EPA (10% wt/wt) than that we used in this study. These different
experimental conditions might explain the differences between their results and ours.
A mechanism underlying the effects of EPA has been previously proposed. First, activation
of Gpr-120/Ffar-4 recruits β-arrestin-2 from the intercellular domain to the plasma membrane,
and this is accompanied by the translocation of TAK-1/MAP3K7 binding protein 1 /MAP3-
K7IP1 (Tab-1), as a binding partner of β-arrestin-2, in macrophages and adipocytes[22]. Sub-
sequently, Tak-1 and its downstream signaling pathway, including JNK and NF-κB, fails to be
activated even in the presence of TNF-α or lipopolysaccharides (LPSs), given the lack of Tab-1
to activate Tak-1. Thus, EPA may inhibit the enlargement of AAAs through activation of Gpr-
120/Ffar-4 by inactivating Tak-1 and the downstream JNK pathway in SMCs. This is consistent
with a study by Yoshimura et al. that reported the prevention of AAA progression by inhibition
of JNK[7].
Based on our results, we propose a model for the inhibitory effects of EPA on AAAs via
SMCs (S4 Fig). EPA reduces Trail-inducedMmp-9 expression by inhibiting the Tak-1-JNK
pathway through Gpr-120/Ffar-4, thereby preventing the enhancement of AAAs. Our findings
may contribute the discovery of therapeutics that suppress the dilatation of aortic aneurysms.
Supporting Information
S1 Fig. EPA does not influence body weight in bothOpg-KO and wild typemice, and aortic
diameter in sham operations. (A)Measurements of body weight at zero, one, and six weeks
after AAA induction with the indicated diet conditions (n = 6–12). (B) Representative images
of aortic samples at zero, one, and six weeks after saline application (sham operation) in wild-
type and Opg-KO mice fed EPA (+) or (-) diets (n = 2–6). Scale bars indicate 1 mm. (C)Mea-
surements of the external aortic diameter at zero, one, and six weeks after AAA induction with
(10 ng/mL). Phosphorylation of Tak-1 and JNK from SMCs, which were cultured with rh-TRAIL, was inhibited by
EPA (D) and GW9508 (E and F). (G) Relative expression levels of Mmp-9 mRNA in SMCs cultured for six hours
with rh-TRAIL (10 ng/mL). Expression of Mmp-9 in SMCs, induced by rh-TRAIL, were inhibited by GW9508. (H-J)
Western blotting analysis for pTak-1/Tak-1 (H) and pJNK/JNK (I) from SMCs, which were treated with scrambled
(NC) or Gpr-120/Ffar-4 siRNA (10 nM) and then cultured with rh-TRAIL (10 ng/mL) for 15 minutes (H) and 30
minutes (I). (J) Relative expression levels of Mmp-9 mRNA from SMCs treated with scrambled (NC) or Gpr-120/
Ffar-4 siRNA (10 nM) and cultured for six hours with rh-TRAIL (10 ng/mL). Data are presented as mean ± SD;
*p<0.05, as compared with controls or Trail alone.
doi:10.1371/journal.pone.0165132.g005
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the indicated diet conditions.
(EPS)
S2 Fig. EPA prevents the up-regulation of Trail inOpg-KO mice.The percentage of stained
areas for Trail in the medial layers was calculated at six weeks for each diet condition. Data are
presented as mean ± SD. The number of samples for analysis (n) is shown in parentheses.
p<0.05, as compared with EPA (-) diet conditions.
(EPS)
S3 Fig. siRNA-mediated knock-downof Gpr-120/Ffar-4 expression. Relative expression lev-
els of Gpr-120/Ffar-4mRNA by qPCR from SMCs cultured with rh-TRAIL (10 mg/mL) for six
hours with or without pre-incubation with EPA (10 μM). Gpr-120/Ffar-4 siRNA was applied
24 hours before pre-incubation with EPA. Data are presented as mean ± SD; p<0.05, as com-
pared with control.
(EPS)
S4 Fig. Schematic of mechanismby which EPA prevents the development of AAAs. In Opg-
KO mice, inflammation triggered by CaCl2 induces the up-regulation of inflammatory cyto-
kines, such as Trail, in SMCs of the aorta. Trail activates the Tak-1-JNK pathway through the
Trail receptor (Trail-R), inducing the expression of genes encoding proteolytic enzymes for the
extracellularmatrix, such asMmp-9 and Trail itself. The enhanced activity of proteolytic
enzymes normally allows for remodeling of the aortic walls, leading to aneurysmal dilatation in
wild-typemice. On the other hand, with the loss of Opg function, continuous expression of
Trail and excessive production of Mmp-9 occur in SMCs. This condition could be a major
cause of the disruption of medial elastic fibers. EPA binds to and activates Gpr-120/Ffar-4 as
a ligand and inhibits Tak-1, resulting in the inactivation of JNK and reduced expression of
Mmp-9.
(EPS)
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